AbbVie's Allergan Aesthetics receives Health Canada approval for Boey
Boey is the first rapid-onset, short-duration botulinum neurotoxin serotype E for glabellar lines.
See the latest news and media coverage for AbbVie. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company
abbvie.comLast updated
In short: AbbVie reported strong first-quarter 2026 results and raised its full-year guidance, driven by growth in its immunology and neuroscience portfolios.
Boey is the first rapid-onset, short-duration botulinum neurotoxin serotype E for glabellar lines.
The approval allows treatment initiation at acute infection diagnosis, aiming to reduce disease progression and support HCV elimination goals.
The approval covers children aged 6 and older, based on Phase 3 trials, and includes a new 55 mg syringe for weight-based dosing.
The deal adds a late-stage IL-13 antibody and other pipeline assets for inflammatory diseases.
By Colin Kellaher AbbVie has won expanded European Commission approvals for its blockbuster autoimmune drug Skyrizi and its hepatitis C drug Maviret. AbbVie on Tuesday...
European Commission Expands Skyrizi Label to Younger PatientsAbbVie (NYSE:ABBV) has received...
AbbVie is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics for abou...
India, June 19 -- The article outlines the significance of the deal and the outlook of the company, which specializes in developing branded generics, specialty...
Track AbbVie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AbbVie and other trending companies.